Dune Medical, a healthcare products manufacturer based in Massachusetts, announced that it received CE Mark clearance from the European Union for its next-generation tissue screening system. According to a press release by the company, the MarginProbe System Type 1.2 console is designed for early-stage breast cancer detection.
In its press release, the company detailed how the MarginProbe device worked. The system is designed to assist surgeons in determining if all cancerous tissue has been excised during early-stage breast cancer operations. Clinical trials have shown that the device is more effective than traditional techniques in detecting remnants of cancerous tissues left behind during lumpectomies.
The new version of the device includes specialized elements that help streamline manufacturing and production costs for the device. In addition, the new version of the device comes in a compact package with improved aesthetic appearance.
Dan Levangie is the CEO of Dune Medical. In prepared remarks, he said, "This new and improved version of the MarginProbe System allows easier transport for our customers and for our sales representatives and we believe will help to expand the use of MarginProbe in more and more breast surgery cases in the EU.”
In January, Dune Medical won approval for the MarginProbe device with the United States Food and Drug Administration. During that time, the company shifted its headquarters from Israel to Massachusetts.